Medison Pharma and Partners Healthcare could be in line for exits after the haematological and musculoskeletal disorder therapy developer filed to raise $86.3m.

US-based musculoskeletal disorder drug developer Keros Therapeutics filed for an $86.3m initial public offering on Monday that could enable healthcare network Partners Healthcare and pharmaceutical services firm Medison Pharma to exit.

Keros is working on therapeutics that will target the Transforming Growth Factor-Beta protein to treat musculoskeletal and haematological disorders with a high unmet need.

The IPO proceeds will partly be used to fund the progression of the company’s lead drug candidate, KER-050, into phase 2 clinical trials for…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.